U.S. scientists try 1st gene editing in the body

Scientists for the first time have tried editing a gene inside the body in a bold attempt to permanently change a person’s DNA to try to cure a disease.

The experiment was done Monday in California on 44-year-old Brian Madeux. Through intravenous (IV), he received billions of copies of a corrective gene and a genetic tool to cut his DNA in a precise spot.

“It’s kind of humbling” to be the first to test this, said Madeux, who has Hunter syndrome, a metabolic disease. “I’m willing to take that risk. Hopefully it will help me and other people.”

Signs of whether it’s working may come in a month; tests will show for sure in three months.

But these methods can only be used for a few types of diseases. Some give results that may not last. Some others supply a new gene like a spare part, but can’t control where it inserts in the DNA, possibly causing a new problem like cancer.

This time, the gene tinkering is happening in a precise way inside the body. It’s like sending a mini-surgeon along to place the new gene in exactly the right location.

“We cut your DNA, open it up, insert a gene, stitch it back up. Invisible mending,” said Dr. Sandy Macrae, president of Sangamo Therapeutics, the California company testing this for two metabolic diseases and hemophilia. “It becomes part of your DNA and is there for the rest of your life.”

That also means there’s no going back — no way to erase any mistakes the editing might cause.

“You’re really toying with Mother Nature” and the risks can’t be fully known, but the studies should move forward because these are incurable diseases, said one independent expert, Dr. Eric Topol of the Scripps Translational Science Institute in San Diego.

Protections are in place to help ensure safety, and animal tests were encouraging, said Dr. Howard Kaufman, a Boston scientist on the National Institutes of Health panel that approved the studies.

He said gene editing’s promise is too great to ignore.

“So far there’s been no evidence that this is going to be dangerous,” he said. “Now is not the time to get scared.”

Woe from head to toe

Fewer than 10,000 people worldwide have these metabolic diseases, partly because many die young. Those with Madeux’s condition, Hunter syndrome, lack a gene that makes an enzyme that breaks down certain carbohydrates. These build up in cells and cause havoc throughout the body.

“Many are in wheelchairs … dependent on their parents until they die,” said Dr. Chester Whitley, a University of Minnesota genetics expert who plans to enrol patients in the studies.

Weekly IV doses of the missing enzyme can ease some symptoms, but cost $100,000 to $400,000 US a year and don’t prevent brain damage.

Madeux, who now lives near Phoenix, is engaged to a nurse, Marcie Humphrey. They met 15 years ago in a study that tested this enzyme therapy at UCSF Benioff Children’s Hospital Oakland, where the gene editing experiment took place.

He has had 26 operations for hernias, bunions, bones pinching his spinal column, and ear, eye and gall bladder problems.

“It seems like I had a surgery every other year of my life” and many procedures in between, he said. Last year, he nearly died from a bronchitis and pneumonia attack. The disease had warped his airway, and “I was drowning in my secretions, I couldn’t cough it out.”

Madeux has a chef’s degree and was part-owner of two restaurants in Utah, cooking for U.S. ski teams and celebrities, but now can’t work in a kitchen or ride horses as he used to.

Gene editing won’t fix damage he has already suffered, but he hopes it will stop the need for weekly enzyme treatments.

Initial studies will involve up to 30 adults to test safety, but the ultimate goal is to treat young children before much damage occurs.

How it works

A gene-editing tool called CRISPR has received a lot of recent attention, but this study used a different one called zinc finger nucleases. They’re like molecular scissors that seek and cut a specific piece of DNA.

The therapy has three parts: The new gene and two zinc finger proteins.

DNA instructions for each part are placed in a virus that has been altered to not cause infection, but to ferry them into cells. Billions of copies of these are given through a vein.

They travel to the liver, where cells use the instructions to make the zinc fingers and prepare the corrective gene. The fingers cut the DNA, allowing the new gene to slip in. The new gene then directs the cell to make the enzyme the patient lacked.

Only one per cent of liver cells would have to be corrected to successfully treat the disease, said Madeux’s physician and study leader, Dr. Paul Harmatz at the Oakland hospital.

“How bulletproof is the technology? We’re just learning,” but safety tests have been very good, said Dr. Carl June, a University of Pennsylvania scientist who has done other gene therapy work, but was not involved in this study.

What could go wrong

Safety issues plagued some earlier gene therapies that weren’t considered gene editing because they didn’t target a specific location in the genome.

One worry is that the virus might provoke an immune system attack. In 1999, Jesse Gelsinger, 18, died in a gene therapy study of that problem, but the new studies use a different virus that’s proved much safer in other experiments.

Another worry is that inserting a new gene might have unforeseen effects on other genes. That happened years ago, when researchers used gene therapy — a procedure that involved inserting the gene into cells outside the body and injecting them back into the body afterward — to cure some cases of the immune system disorder called “bubble boy” disease. Several patients later developed leukemia because the new gene inserted into a place in the native DNA where it unintentionally activated a cancer gene.

“When you stick a chunk of DNA in randomly, sometimes it works well, sometimes it does nothing and sometimes it causes harm,” said Hank Greely, a Stanford University bioethicist. “The advantage with gene editing is you can put the gene in where you want it.”

Finally, some fear that the virus could get into other places like the heart, or eggs and sperm, where it could affect future generations. Doctors say built-in genetic safeguards prevent the therapy from working anywhere but the liver, like a seed that only germinates in certain conditions.

This experiment is not connected to other, more controversial work being debated to try to edit genes in human embryos to prevent diseases before birth — changes that would be passed down from generation to generation.

Making history

Madeux’s treatment was to have happened a week earlier, but a small glitch prevented it.

He and his fiancée returned to Arizona, but nearly didn’t make it back to Oakland in time for the second attempt because their Sunday flight was cancelled and no others were available until Monday, after the treatment was to take place.

Scrambling, they finally got a flight to Monterey, Calif., and a car service took them just over 160 kilometres north to Oakland.

On Monday, he had the three-hour infusion, surrounded by half a dozen doctors, nurses and others wearing head-to-toe protective garb to lower the risk of giving him any germs. His doctor, Harmatz, spent the night at the hospital to help ensure his patient stayed well.

“I’m nervous and excited,” Madeux said as he prepared to leave the hospital. “I’ve been waiting for this my whole life, something that can potentially cure me.”

More About

BY LAURIE MCGINLEY
WASHINGTON POST
In a historic move, the Food and Drug Administration on Tuesday approved a pioneering gene therapy for a rare form of childhood blindness, the first such treatment cleared in the United States for an inherited disease.
The approval signals a new era for gene therapy, a field that struggled for decades to overcome devastating setbacks but now is pushing forward in an effort to develop treatments for hemophilia, sickle-cell anemia and an array of other genetic diseases. Yet the products, should they reach patients, are likely to carry stratospheric prices — a prospect already worrying consumer advocates and economists.
Philadelphia-based Spark Therapeutics, which makes the childhood-blindness treatment, said it will not announce the price until January. Analysts speculate it could be as much as $1 million for both eyes.

genomic privacy

BY CURTIS AND HEREWARD
THE CONVERSATION
We are approaching a time when you might be too scared to have your genome sequenced. Only last week, a US senator called for an investigation into the privacy policies of direct-to-consumer DNA companies.

There is something like gold flowing through the veins of 100-year-old Maria Tegas, and everyone wants a piece of the treasure. The centenarian, who lives in a poor and remote area of central eastern Sardinia – in one of 14 villages known to geneticists and genealogists as the Blue Zone – has not had an easy life.

professional regulation

BY TOM IRELAND
THE GUARDIAN
Josiah Zayner, 36, recently made headlines by becoming the first person to use the revolutionary gene-editing tool Crispr to try to change their own genes. Part way through a talk on genetic engineering, Zayner pulled out a syringe apparently containing DNA and other chemicals designed to trigger a genetic change in his cells associated with dramatically increased muscle mass.

BY AMY DOCKSER MARCUS
WALL STREET JOURNAL
Kian Sadeghi has postponed homework assignments, sports practice and all the other demands of being a 17-year-old high-school junior for today. On a Saturday afternoon, he is in a lab learning how to use Crispr-Cas9, a gene-editing technique that has electrified scientists around the world—and sparked a widespread debate about its use.

emerging technologies

BY LAURIE MCGINLEY
WASHINGTON POST
In a historic move, the Food and Drug Administration on Tuesday approved a pioneering gene therapy for a rare form of childhood blindness, the first such treatment cleared in the United States for an inherited disease. The approval signals a new era for gene therapy, a field that struggled for decades to overcome devastating setbacks but now is pushing forward in an effort to develop treatments for hemophilia, sickle-cell anemia and an array of other genetic diseases. Yet the products, should they reach patients, are likely to carry stratospheric prices — a prospect already worrying consumer advocates and economists.

The Associated Press
CBC.ca
Scientists for the first time have tried editing a gene inside the body in a bold attempt to permanently change a person's DNA to try to cure a disease. The experiment was done Monday in California on 44-year-old Brian Madeux.

gene patents

BY ANDRÉ PICARD
THE GLOBE AND MAIL
‘Gene patents no longer need to stand in the way of diagnosing life-threatening disease.”
That’s how Alex Munter, president and chief executive officer of the Children’s Hospital of Eastern Ontario, summed up the impact of an out-of-court settlement in the lawsuit CHEO launched against Transgenomic Inc. in 2014. Transgenomic, a biotechnology company based in Omaha, Neb., owns five gene patents related to the potentially deadly heart condition Long QT syndrome.

BY MICHAEL SLEZAK
NEWSCIENTIST
Your genes are no longer patentable in Australia. The country’s highest court found unanimously that two previous Australian judgments allowing patents of genes were wrong, and they do not constitute a patentable invention.

Search

Archives

Archives

In Case You Missed It

BY KELLY SERVICK
SCIENCE
The molecular diagnostics company Myriad Genetics has put an end to a long battle to defend controversial patents on genetic tests for cancer risk. Several of the companies Myriad was suing for patent infringement announced settlements this week, and The New York Times reports that the company is in discussions to settle the remaining suits.